For over 35 years, ePTFE has been a mainstay of the cardiovascular device … [Read More...]
White Papers
Insights Into Drug Delivery Device Manufacturing From Development Through Commercialization
Biologics and other targeted therapies are creating opportunities for … [Read More...]
Sponsored Content
The need for new business models under MDR/IVDR
In less than 12 months, the world’s second largest market for medical technologies is going to be turned upside down. The new medical devices regulation (MDR) and in vitro diagnostic device regulation … [Read More...]
Outcome-based Pricing Initiatives in the Healthcare Industry
By Joe Miles - Global Vice President, Life Sciences (SAP Industries) and Bob Steller - Industry Principle, Life Sciences (Vistex) A distorted reimbursement model has driven healthcare costs ever … [Read More...]
5 Guidelines for Writing a Useful Clinical Monitoring Report
Taking Your Report from Good to Great By Brandy Chittester, Chief of Clinical Operations A well-written monitoring report is an essential part of documenting clinical trial oversight. In addition … [Read More...]
Mergers & Acquisitions.
Edwards Lifesciences closes $98m CAS Medical Systems buyout
Edwards Lifesciences (NYSE:EW) yesterday closed the $98 million acquisition of CAS Medical Systems and its non-invasive brain tissue oxygenation monitoring tech. Irvine, Calif.-based Edwards paid $2.45 per share for Branford, Conn.-based Casmed using cash on hand, for an aggregate value of $98.1 million, Casmed said in a regulatory filing. The deal was announced Feb. 12. The […]
Medline Industries buys Namic business from AngioDynamics
Medline Industries will pay $167.5 million to acquire the Namic fluid management business from AngioDynamics (NSDQ:ANGO), the companies announced today. The deal, subject to customary closing conditions, is expected to close in the summer. It will allow Medline to acquire the manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories offered […]
Smith & Nephew closes Osiris Therapeutics, Leaf Healthcare buys
Smith & Nephew (NYSE:SNN) said today that it closed both its $660 million acquisition of Osiris Therapeutics (NSDQ:OSIR) and its purchase of Leaf Healthcare and its Leaf Patient Monitoring System. The London-based company said that it paid $19 per share in cash for Osiris, which develops and produces regenerative medicine products including skin, bone grafts and articular […]
Obalon taps Cowen to explore ‘strategic alternatives’
Obalon Therapeutics (NSDQ:OBLN) today tapped an advisory firm to explore “strategic alternatives,” a week after revealing plans to cut its workforce in half. The Carlsbad, Calif.-based company, which makes a gas-filled balloon designed to treat obesity, said April 3 that it would lay off 49 of its 100 employees, including all of its direct sales force, […]
Admedus deals vaccines biz to Constellation Therapeutics
Admedus (ASX:AHZ) said today that it agreed to sell its vaccines business to Constellation Therapeutics in a deal that will see it own nearly 30% of the Chinese company. Other shareholders in the vaccines would own another 11%, Queensland, Australia-based Admedus said. Sun Bright Holdings will own the remainder and put in $18 million until November […]
FTC grants final approval for Fresenius’s $2B buyout of NxStage
The U.S. Federal Trade Commission said yesterday that it granted a final order of approval to Fresenius Medical Care (NYSE:FMS; ETR:FRE) for its $2 billion acquisition of NxStage Medical. The approval came with a caveat that the companies divest their assets and rights to research, develop, manufacture, market and sell NxStage’s bloodline tubing sets intended for use […]
Histogenics to merge with Ocugen
Histogenics (NSDQ:HSGX) said yesterday that it inked a definitive merger agreement with Ocugen through which both companies will combine into a single publicly-traded, clinical-stage biopharmaceutical company. The combined entity will operate under the Ocugen name, the companies said. As part of the deal, Ocugen’s shareholders will become the majority owners of Histogenics outstanding common stock upon […]
MassDevice Network
@MassDevice
LinkedIn
YouTube